Clinical Trial: A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06888921) titled 'A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer' on March 12.

Brief Summary: The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701.

The main questions the trial aims to answer are:

* Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer?

* Does COM701 delay the time to needing a new anti-cancer treatment?

* What side effects do participants have when...